Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC.

Methods

Every 4 weeks, the patients received irinotecan 50 mg/m2 (days 1, 8 and 15) and carboplatin (day 1) with a target AUC of 5 mg min/ml using the Chatelut formula.

Results

All patients were evaluable for toxicity, and of 59 patients evaluable for response, 20 achieved a partial response and 26 showed no change. The overall response rate was 34% (95% confidence interval 23–48%). Grade 3 or 4 anemia, leukopenia, neutropenia, thrombocytopenia and diarrhea occurred in 32%, 32%, 60%, 25%, and 7%, respectively. The median survival time and 1-year, and 2-year survival rates were 10.0 months, 37.6%, and 15.2%, respectively.

Conclusions

Irinotecan with carboplatin is effective for advanced NSCLC and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722

    CAS  PubMed  Google Scholar 

  2. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715

    CAS  PubMed  Google Scholar 

  3. Masuda N, Kudoh S, Fukuoka M (1996) Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 24:3

    Article  CAS  PubMed  Google Scholar 

  4. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in a human small cell lung cancer cells. Cancer Res 56:789

    CAS  PubMed  Google Scholar 

  5. Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res 17:113

    Article  CAS  PubMed  Google Scholar 

  6. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50:5919

    CAS  PubMed  Google Scholar 

  7. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H (1998) Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br J Cancer 78:251

    CAS  PubMed  Google Scholar 

  8. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M, CPT-11 Lung Cancer Study Group West (2003) Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335

    Article  CAS  PubMed  Google Scholar 

  9. Niho S, Nagao K, Nishiwaki Y, Yokoyama A, Saijo N, Ohashi Y, Niitani H, The Irinotecan Lung Cancer Study Group (1999) Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:492a

    Google Scholar 

  10. De Vore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL (1999) Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 17:2710

    PubMed  Google Scholar 

  11. Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12:1

    Article  CAS  Google Scholar 

  12. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9:13

    Article  CAS  PubMed  Google Scholar 

  13. Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20:23S

    CAS  PubMed  Google Scholar 

  14. Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S (1999) Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 5:3936

    Google Scholar 

  15. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748

    CAS  PubMed  Google Scholar 

  16. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing schema for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylato-platinum. Cancer Res 45:6502

    CAS  PubMed  Google Scholar 

  17. Duffull SB, Robinso BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161

    CAS  PubMed  Google Scholar 

  18. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573

    CAS  PubMed  Google Scholar 

  19. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718

    CAS  PubMed  Google Scholar 

  20. WHO (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva

    Google Scholar 

  21. Simon R (1987) How large should be a phase II trial of a new drug? Cancer Treat Rep 71:1079

    CAS  PubMed  Google Scholar 

  22. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457

    Google Scholar 

  23. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92

    Article  CAS  PubMed  Google Scholar 

  24. Takeda K, Negoro S, Ohashi Y, Saijo N, Nishiwaki Y, Tamura T, Nakagawa K, Kubota K, Ariyoshi Y, Fukuoka M (2003) Preliminary results of four arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. Lung Cancer 41:S64

    Article  Google Scholar 

  25. Takeda K, Takefuji N, Uejima H, Yoshimura N, Terakawa K, Negoro S (2002) Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer 38:303

    Article  PubMed  Google Scholar 

  26. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Respiratory Disease, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

    Minoru Fukuda & Mikio Oka

  2. Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan

    Hiroshi Soda, Junji Tsurutani, Yoichi Nakamura, Takashi Kasai, Yuichi Inoue & Shigeru Kohno

  3. National Nagasaki Medical Center, Nagasaki, Japan

    Akitoshi Kinoshita

  4. Japanese Red-Cross Nagasaki Atomic Bomb Hospital, Nagasaki, Japan

    Masaaki Fukuda

  5. Sasebo General Hospital, Nagasaki, Japan

    Seiji Nagashima

  6. National Okinawa Hospital, Okinawa, Japan

    Mutsuo Kuba

  7. Nagasaki Municipal Hospital, Nagasaki, Japan

    Hiroshi Takatani

  8. National Ureshino Hospital, Saga, Japan

    Yoshifumi Soejima

Authors
  1. Minoru Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikio Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Soda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akitoshi Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaaki Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiji Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mutsuo Kuba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Takatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junji Tsurutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoichi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takashi Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuichi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshifumi Soejima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shigeru Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Nagasaki Thoracic Oncology Group

Corresponding author

Correspondence to Minoru Fukuda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukuda, M., Oka, M., Soda, H. et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 54, 573–577 (2004). https://doi.org/10.1007/s00280-004-0805-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0805-2

Keywords

Search

Navigation